January 22, 2021 Baker Brothers Investments New York, NY 10014Director and Observer Rights Agreement • May 20th, 2021 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances)
In connection with the 27,457,400 series C preferred shares with a nominal value of £0.0001 each in the share capital of Immunocore Holdings Limited (the “Company”) held by funds advised by Baker Bros. Advisors LP (“BBA”) (together, the “Shares”), the parties to this letter agreement (the “Letter Agreement”) hereby set forth herein and further agree as follows:
